Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Shares Outstanding (Diluted Average): 2013-2025

Historic Shares Outstanding (Diluted Average) for Agios Pharmaceuticals (AGIO) over the last 6 years, with Sep 2025 value amounting to $58.1 million.

  • Agios Pharmaceuticals' Shares Outstanding (Diluted Average) fell 0.50% to $58.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.1 million, marking a year-over-year decrease of 0.50%. This contributed to the annual value of $57.9 million for FY2024, which is 4.02% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $58.1 million, which was up 0.36% from $57.9 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $69.5 million in Q1 2021 and a low of $54.6 million during Q1 2022.
  • In the last 3 years, Agios Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $56.8 million in 2024 and averaged $56.9 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Shares Outstanding (Diluted Average) fell by 21.55% in 2022, and later grew by 4.71% in 2024.
  • Agios Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $60.4 million in 2021, then declined by 9.36% to $54.8 million in 2022, then climbed by 1.57% to $55.7 million in 2023, then increased by 4.02% to $57.9 million in 2024, then decreased by 0.50% to $58.1 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $58.1 million in Q3 2025, compared to $57.9 million in Q2 2025 and $57.5 million in Q1 2025.